Two anti-angiogenic agents are better than one when it comes to disrupting mesothelioma tumor growth and slowing down the cancer’s progress. Researchers from Hyogo College of Medicine in Japan revealed last month that using multiple anti-angiogenic factors as gene therapy agents increases effectiveness against mesothelioma because this approach permits an attack on more than one